Maturation inhibitor

From Wikipedia, the free encyclopedia

Jump to: navigation, search

A Maturation inhibitor is a class of antiviral drug.

An example is bevirimat.[1][2]

[edit] References

  1. ^ Stoddart CA, Joshi P, Sloan B, et al. (2007). "Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice". PLoS ONE 2 (11): e1251. doi:10.1371/journal.pone.0001251. PMID 18043758. PMC 2080775. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001251. 
  2. ^ Salzwedel K, Martin DE, Sakalian M (2007). "Maturation inhibitors: a new therapeutic class targets the virus structure". AIDS Rev 9 (3): 162–72. PMID 17982941. http://www.aidsreviews.com/resumen.asp?id=970&indice=200793&u=unp. 
v • d • e
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Entry/fusion inhibitors
(Discovery & development)
Reverse transcriptase
inhibitors (RTIs)
(1st gen) Efavirenz°# · Nevirapine#  · Loviride◊ · Delavirdine◊ ·
 (2nd gen) diarylpyrimidines (Etravirine, Rilpivirine†)  · Lersivirine†
Integrase inhibitors
Raltegravir · Elvitegravir† · Globoidnan A (experimental)  · MK-2048†  · GSK-572†
Maturation inhibitors
Bevirimat† · Vivecon†
Protease Inhibitors (PI)
(Discovery & development)
Combined formulations
Experimental agents
TRIM5alpha (gene)
Other
Failed agents
#WHO-EM. ‡Withdrawn from market. CLINICAL TRIALS: †Phase III. §Never to phase III
°DHHS preferred first-line agent. ◊Formerly or rarely used agent.


Stub icon This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org/wiki/Maturation_inhibitor"